AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors

In a report published Friday, Evercore ISI analyst Mark Schoenebaum mentioned the abstracts and companies he would be tracking during the upcoming AAIC.

This could include aducanumab by Biogen Inc (NASDAQ: BIIB) and solanezumab by Eli Lilly and Co (NYSE: LLY).

AAIC is scheduled between July 18 and 22. Analyst Mark Schoenebaum noted the planner for abstracts that they would be will be tracking:

Saturday - July 18

• POSTER

Comparison of Reference Regions for Improved Detection of Change in Florbetapir PET from Phase 3 Solanezumab Trials
Exhibit Hall E
IC-P-030
12:15pm - 2:15pm

Tuesday - July 21

• POSTER

Safety of Solanezumab in the Expedition-EXT Study up to 2 Years in a Mild to Moderate Alzheimer's Disease Population
Exhibit Hall D
P3-285
9:30am - 4:15pm

• ORAL

Comparison of Reference Regions for Improved Detection of Change in Florbetapir PET from Phase 3 Solanezumab Trials
Hall E
03-01-04
2:00pm - 3:30pm

Wednesday – July 22

• ORAL

Delayed-Start Analyses of up to 3.5 Years in the Phase 3 Solanezumab Expedition Program in Mild Alzheimer's Disease
Ballroom A
04-03-02
8:00am - 9:30am

• POSTER

Rvt-101, a 5-HT6 Receptor Antagonist, As Adjunctive Therapy with Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Responder Analysis
Exhibit Hall E
P4-302
9:30am - 4:15pm

• ORAL

Aducanumab (BIIB037), an Anti-Amyloid Beta Monoclonal Antibody, in Patients with Prodromal or Mild Alzheimer's Disease: Interim Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1B Study
146
04-04-05
2:00pm - 3:30pm

• ORAL

The Efficacy of Rvt-101, a 5-HT6 Receptor Antagonist, As an Adjunct to Donepezil in Adults with Mild-to-Moderate Alzheimer's Disease: Completer Analysis of a Phase 2b Study
Hall E
DT-01-04
2:00pm - 3:30pm

• Axovant Investor Briefing

Doors open at 5:15pm
Presentation begins 5:45pm
Marriott Marquis, Georgetown Room, 900 Massachusetts Ave. Northwest, Washington, DC 20001